Immune-mediated disorders among women carriers of fragile X premutation alleles.
The relative risk of immune-mediated disorders (IMDs) among women carriers of premutation alleles is estimated by a survey for IMDs among 344 carrier women (age 19-81 years; mean 46.35 and SD 12.60) and 72 controls (age 18-87 years; mean 52.40 and SD 15.40). One hundred fifty four (44.77%) women carrier had at least one IMD, as did 20 controls (27.78%). Among women carriers, autoimmune thyroid disorder was the most common (24.4%), then fibromyalgia (10.2%), irritable bowel syndrome (IBS; 9.9%), Raynaud's phenomenon (7.6%), rheumatoid arthritis (RA; 3.8%), Sjögren syndrome (2.6%), systemic lupus erythematosus (SLE; 2.03%), multiple sclerosis (1.74%). Of 55 carriers age 40 or older with FXTAS, 72.73% had at least one IMD, compared to 46.54% of those without FXTAS (n = 159), and 31.58% of controls (n = 57). The estimated odds ratio (OR) for IMD is 2.6 (95% CI 1.2-5.6, P = 0.015) for women with FXTAS relative to those without FXTAS; the likelihood of IMD in carriers without or with FXTAS was also significantly higher than for controls (OR 2.1, 95% CI 1.1-4.2, P = 0.034; OR 5.5, 95% CI 2.4-12.5, P < 0.001, respectively). Similarly, the odds of having an IMD among carriers with FXPOI is about 2.4 times higher when compared to carriers without FXPOI (95% CI 1.1-5.0; P = 0.021). The likelihood of IMD in carriers with or without FXPOI is greater (OR 2.4, 95% CI 1.1-5.0; P = 0.021) compared to that of controls.
Medical Investigation of Neurodevelopmental Disorders Institute, University of California, Davis, Health System, Sacramento, USA.
Tri Indah
TI
Winarni
Weerasak
W
Chonchaiya
Tanjung Ayu
TA
Sumekar
Paul
P
Ashwood
Guadalupe Mendoza
GM
Morales
Flora
F
Tassone
Danh V
DV
Nguyen
Sultana M H
SM
Faradz
Judy
J
Van de Water
Kylee
K
Cook
Alyssa
A
Hamlin
Yi
Y
Mu
Paul J
PJ
Hagerman
Randi J
RJ
Hagerman
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D001259:Ataxia / Q000235:genetics; D001327:Autoimmune Diseases / Q000453:epidemiology* / Q000235:genetics*; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics*; D005600:Fragile X Syndrome / Q000150:complications* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D014202:Tremor / Q000235:genetics; D019680:Trinucleotide Repeat Expansion; D055815:Young Adult
D051860:Fragile X Messenger Ribonucleoprotein 1; C497683:FMR1 protein, human